Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2015 1
2016 4
2017 3
2018 2
2019 6
2020 3
2021 11
2022 6
2023 7
2024 14
2025 18
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial.
Gunsch PA, Kroesen M, Debets R, Keereweer S, van Meerten E, Zindler J, van Werkhoven E, Hoogeman M, Verduijn GM, Nout RA, Elbers JBW. Gunsch PA, et al. Clin Transl Radiat Oncol. 2026 Jan 25;58:101113. doi: 10.1016/j.ctro.2026.101113. eCollection 2026 May. Clin Transl Radiat Oncol. 2026. PMID: 41685200 Free PMC article.
We aim to reduce treatment burden and RIL using HYpofractionation and Dose-redistribution in patients treated with proton or photon RAdiotherapy (HYDRA, NCT05364411). METHODS: Patients receiving curative (chemo)radiotherapy for cT1-4 N0-3bM0 oropharyngeal and hypopharyngea …
We aim to reduce treatment burden and RIL using HYpofractionation and Dose-redistribution in patients treated with proton or photon R …
Impact of center-to-center distance and slit width on robust target coverage and PVDR for proton minibeam radiation therapy using a commercial TPS.
Prins AC, Traneus E, Hoogeman MS, Ng Wei Siang K. Prins AC, et al. Med Phys. 2026 Feb;53(2):e70340. doi: 10.1002/mp.70340. Med Phys. 2026. PMID: 41665563 Free PMC article.
BACKGROUND: Proton minibeam radiation therapy (pMBRT) is a novel technique that may reduce normal tissue toxicity through spatial fractionation of proton beams. ...
BACKGROUND: Proton minibeam radiation therapy (pMBRT) is a novel technique that may reduce normal tissue toxicity through spat …
Probabilistic proton treatment planning: a novel approach for optimizing underdosage and overdosage probabilities of target and organ structures.
de Jong JR, Breedveld S, M Habraken SJ, Hoogeman MS, Lathouwers D, Perkó Z. de Jong JR, et al. Phys Med Biol. 2026 Jan 20;71(2). doi: 10.1088/1361-6560/ae351c. Phys Med Biol. 2026. PMID: 41556543
Margin-based methods expand the clinical target volume (CTV) towards a planning target volume, which is generally unsuited for proton therapy. Robust optimization considers worst-case scenarios, but its quality depends on the chosenuncertainty (scenario) set: exclud …
Margin-based methods expand the clinical target volume (CTV) towards a planning target volume, which is generally unsuited for proton …
An ESTRO-EPTN Delphi consensus on robustness evaluation in proton therapy.
Fracchiolla F, Meijers A, Orlandi E, Korevaar E, Whitfield G, Jensen K, Hoogeman M, Wijsman R, Jouglar E, Weerd EV, Pérez JM, Rinaldi I, Garbacz-Stryszewska M, Cianchetti M, Feijoo MM, Molinelli S, Elstrøm UV, Pica A, Gosling A, Koczur B, Dahlgren CV, Alterio D, Dale E, Farid G, Compter I, Doyen J, Dale JE, Färlin J, Urbanek K, Fjæra LF, Lambrecht M, Ugland M, Tschiche M, Vidal M, Lowe M, Bütof R, Gulliford S, Comi S, Habraken S, Tessonnier T, Sterpin E, Widesott L. Fracchiolla F, et al. Phys Imaging Radiat Oncol. 2025 Dec 30;37:100900. doi: 10.1016/j.phro.2025.100900. eCollection 2026 Jan. Phys Imaging Radiat Oncol. 2025. PMID: 41550258 Free PMC article.
BACKGROUND AND PURPOSE: Robustness evaluation (RE) is vital for proton treatment planning, but lacks international consensus or guidelines, with clinics using varied, self-developed methods focused on selected uncertainties. ...MATERIALS AND METHODS: A study within the Eur …
BACKGROUND AND PURPOSE: Robustness evaluation (RE) is vital for proton treatment planning, but lacks international consensus or guide …
Photon-counting computed tomography for stopping power ratio prediction in proton therapy.
Huijskens S, van Straten M, Lopes PC, Rossi L, Wohlfahrt P, Hoogeman M. Huijskens S, et al. Med Phys. 2025 Dec;52(12):e70146. doi: 10.1002/mp.70146. Med Phys. 2025. PMID: 41255099 Free PMC article.
BACKGROUND: A substantial source of error in proton therapy is predicting the stopping power ratio (SPR) of tissues from computed tomography (CT). ...Mean absolute errors (MAE) over the inserts were calculated for each imaging modality in both body and head configur …
BACKGROUND: A substantial source of error in proton therapy is predicting the stopping power ratio (SPR) of tissues from compu …
Automatic target delineation for online adaptive H&N IMPT with a plan library approach - A feasibility study.
Giżyńska MK, Oud M, Breedveld S, Heijmen BJM, Hoogeman M. Giżyńska MK, et al. Phys Med. 2025 Nov;139:105191. doi: 10.1016/j.ejmp.2025.105191. Epub 2025 Oct 23. Phys Med. 2025. PMID: 41135171
PURPOSE: Plan library (PL) based, online adaptive intensity modulated proton therapy (IMPT) was recently proposed for head-and-neck (HN) cancer. In this approach, a set of robust treatment plans is generated prior to the fractionated treatment, each with a different …
PURPOSE: Plan library (PL) based, online adaptive intensity modulated proton therapy (IMPT) was recently proposed for head-and …
Probabilistic evaluation guided IMPT planning with realistic setup and range uncertainties improves the trade-off between OAR sparing and target coverage in neuro-oncological patients.
de Jong JI, Habraken SJM, Rojo-Santiago J, Lathouwers D, Perkó Z, Breedveld S, Hoogeman MS. de Jong JI, et al. Radiother Oncol. 2025 Dec;213:111171. doi: 10.1016/j.radonc.2025.111171. Epub 2025 Sep 27. Radiother Oncol. 2025. PMID: 41022254
OBJECTIVE: Scenario-based evaluation in proton therapy often relies on a small number of error scenarios, leading to limited insight into the DVH values under uncertainty and suboptimal trade-offs. ...
OBJECTIVE: Scenario-based evaluation in proton therapy often relies on a small number of error scenarios, leading to limited i …
Impact assessment of current knowledge gaps and mitigation strategies in clinical FLASH proton therapy through a systematic review.
Zur Horst AH, Habraken SJM, Rovituso M, Klaver YLB, Spruijt KH, Hoogeman MS. Zur Horst AH, et al. Front Oncol. 2025 Sep 11;15:1550264. doi: 10.3389/fonc.2025.1550264. eCollection 2025. Front Oncol. 2025. PMID: 41018099 Free PMC article.
INTRODUCTION: Following first clinical trials, the development of FLASH proton therapy (FLASH-PT) into a mature treatment modality is ongoing, while physical and biological conditions underlying the FLASH effect remain uncertain. ...
INTRODUCTION: Following first clinical trials, the development of FLASH proton therapy (FLASH-PT) into a mature treatment moda …
74 results